Evelo Biosciences (EVLO) Stock Price, News & Analysis

Company Overview

Evelo Biosciences, Inc. was a clinical-stage biotechnology company focused on developing orally administered medicines that act through the small-intestinal axis. The company’s approach was designed to use specific strains of bacteria or microbial products to influence immune and inflammatory responses throughout the body.

Evelo’s research platform, known as SINTAX, supported the development of product candidates for inflammatory, autoimmune and oncology indications. Its lead programs included EDP1815, an oral microbial therapeutic studied in conditions such as psoriasis and atopic dermatitis, and EDP2939, which was investigated as an immune-modulating treatment for cancer. The company conducted clinical development activities in the United States and other regions.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Evelo Biosciences was formerly listed on the Nasdaq under the symbol EVLO. The company later entered a wind-down process after pursuing strategic alternatives and financial restructuring, and its operations and development programs were substantially discontinued. Because the company is no longer an active biotechnology developer, historical information about its programs represents its activities before that wind-down.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 2,227 shs
• Market Capitalization: $2 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 10/27/2021
• Today: 10/04/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:EVLO
• CIK: 1694665
• Web: www.evelobio.com
• Phone: (617) 577-0300
• Fax: N/A
• Employees: 66
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,840,000
• Free Float: 18,789,000
• Market Cap: $2 thousand
• Optionable: No Data
• Beta: 1.50